Pascal Furet Selected Research

Investigational Drugs

1/2018

Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pascal Furet Research Topics

Disease

29	Neoplasms (Cancer) 01/2022 - 02/2002
5	Leukemia 01/2018 - 02/2002
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 03/2004
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 09/2004
2	Neoplasm Metastasis (Metastasis) 01/2017 - 12/2002
2	Breast Neoplasms (Breast Cancer) 03/2012 - 06/2009
1	Liver Neoplasms (Liver Cancer) 12/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019
1	Systemic Mastocytosis 01/2018
1	Philadelphia Chromosome 01/2017
1	Cholangiocarcinoma 01/2017
1	Pulmonary Arterial Hypertension 01/2016
1	Endometriosis 03/2012
1	Vascular Remodeling 09/2010
1	Polycythemia (Erythrocytosis) 07/2010
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 03/2010
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2004
1	Colorectal Neoplasms (Colorectal Cancer) 03/2004
1	Melanoma (Melanoma, Malignant) 12/2002

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 01/2018 - 01/2003
8	Proteins (Proteins, Gene)FDA Link 01/2019 - 10/2002
7	Phosphotransferases (Kinase)IBA 01/2018 - 02/2002
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 12/2002
4	NVP-CGM097IBA 11/2018 - 05/2015
4	Imatinib Mesylate (Gleevec)FDA Link 08/2011 - 02/2002
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2009 - 02/2002
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 05/2014
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2015
2	LigandsIBA 01/2019 - 09/2010
2	midostaurinIBA 01/2018 - 12/2008
2	Oncogene Proteins (Oncogene Protein)IBA 01/2018 - 12/2004
2	Aromatase (CYP19)IBA 03/2012 - 06/2009
2	Estrogen ReceptorsIBA 03/2012 - 06/2009
2	vatalanib (PTK787)IBA 06/2009 - 03/2004
2	Tyrosine Kinase InhibitorsIBA 06/2009 - 03/2004
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2009 - 07/2008
2	Protein Kinases (Protein Kinase)IBA 12/2008 - 02/2002
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2004 - 02/2002
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2003 - 02/2002
1	roblitinibIBA 12/2019
1	capmatinibIBA 01/2019
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2019
1	siremadlinIBA 11/2018
1	Investigational DrugsIBA 01/2018
1	Protein Kinase InhibitorsIBA 01/2018
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2017
1	Circulating Tumor DNAIBA 01/2017
1	infigratinibIBA 01/2017
1	asciminibIBA 01/2017
1	Cell-Free Nucleic AcidsIBA 01/2017
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2016
1	Proto-Oncogene Proteins c-mdm2IBA 08/2015
1	AlpelisibIBA 05/2014
1	Tyrosine (L-Tyrosine)FDA Link 08/2011
1	Erythropoietin FDA Link 07/2010
1	Phenylalanine (L-Phenylalanine)FDA Link 07/2010
1	Amino Acids FDA Link 07/2010
1	QuinoxalinesIBA 07/2010
1	Valine (L-Valine)FDA Link 07/2010
1	NVP-BSK805IBA 07/2010
1	Angiogenesis InhibitorsIBA 06/2009
1	Adenosine Triphosphate (ATP)IBA 01/2009
1	PoisonsIBA 01/2009
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2009
1	EnzymesIBA 01/2009
1	NVP-AST487IBA 12/2008
1	Indicators and Reagents (Reagents)IBA 12/2008
1	TOR Serine-Threonine KinasesIBA 07/2008
1	dactolisibIBA 07/2008
1	Bevacizumab (Avastin)FDA Link 03/2004
1	Monoclonal AntibodiesIBA 03/2004
1	Peptides (Polypeptides)IBA 10/2002
1	tyrosine receptor (receptor, tyrosine)IBA 02/2002
1	PKI 166IBA 02/2002
1	ErbB Receptors (EGF Receptor)IBA 02/2002

Therapy/Procedure

12	Therapeutics 01/2021 - 03/2004
1	Drug Therapy (Chemotherapy) 02/2002